AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11693277 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS Multilink Duet stent
Number of subjects: 240
Study 9822086 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting in vessels >=3 mm (Group I)
Number of subjects: 1298
Study 9822086 — intervention group
Group type: COMPARATOR
Intervention: Stenting in vessels <3 mm (Group II)
Number of subjects: 1298
Study 7853449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball-bouncing (diverted attention)
Number of subjects: 38
Study 7853449 — intervention group
Group type: COMPARATOR
Intervention: Calm seated (focused attention)
Number of subjects: 38
Study 2570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 105
Study 2570233 — intervention group
Group type: EXPERIMENTAL
Intervention: Azapropazone
Number of subjects: 105
Study 72290 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oxprenolol
Number of subjects: 24
Study 30714980 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) plus traditional dysphagia training (n = 17)
Number of subjects: 33
Study 30714980 — intervention group
Group type: COMPARATOR
Intervention: Traditional dysphagia training alone (n = 16)
Number of subjects: 33
Study 28878437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive health guidance using IoT devices (measuring daily activity, body weight, and blood pressure)
Number of subjects: 101
Study 28878437 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical guidance (non-IoT control group with measurement devices without feedback)
Number of subjects: 101
Study 26836126 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate (CS) and deproteinized bovine bone (group CB)
Number of subjects: 16
Study 26836126 — intervention group
Group type: COMPARATOR
Intervention: Biphasic CS and alloplast (group CA)
Number of subjects: 16
Study 24655119 — intervention group
Group type: EXPERIMENTAL
Intervention: IV alcohol infusion to attain and clamp the breath alcohol concentration (BrAC) at 50 mg%
Number of subjects: 24
Study 24655119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 22153056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco control course
Number of subjects: 546
Study 22153056 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 546
Study 19410948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic foldable aspherical IOL (Tecnis ZA9003)
Number of subjects: 41
Study 19410948 — intervention group
Group type: COMPARATOR
Intervention: Acrylic foldable spherical IOL (AR40e)
Number of subjects: 41
Study 19410948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic foldable aspherical IOL (Tecnis ZA9003) and Acrylic foldable spherical IOL (AR40e)
Number of subjects: 41
Study 17884351 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized cannabis extract containing Delta(9)‐THC and cannabidiol (CBD)
Number of subjects: 22
Study 17884351 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta(9)‐THC
Number of subjects: 22
Study 17884351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 22
Study 15198448 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely disabled cohort
Number of subjects: 0
Study 15198448 — intervention group
Group type: COMPARATOR
Intervention: Benign cohort
Number of subjects: 0
Study 12371348 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidcombe Program for 12 weeks
Number of subjects: 23
Study 12371348 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural recovery)
Number of subjects: 23
Study 11783270 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongbu No. 1 (TB1)
Number of subjects: 56
Study 7751487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 54
Study 7751487 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 54
Study 2125864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture stimulation (Hegu and Neiguan)
Number of subjects: 40
Study 2125864 — intervention group
Group type: COMPARATOR
Intervention: Superficial cervical plexus block
Number of subjects: 40
Study 2125864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric acupuncture stimulation (Hegu and Neiguan) with intravenous Pethedine (1.3 mg/kg)
Number of subjects: 40
Study 2125864 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 5% Glucose during operation
Number of subjects: 40
Study 2125864 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40
Study 6772889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult day care services
Number of subjects: 0
Study 6772889 — intervention group
Group type: COMPARATOR
Intervention: Existing Medicare services
Number of subjects: 0
Study 6772889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult day care services + Existing Medicare services
Number of subjects: 0
Study 30670438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 1,200 mg once weekly
Number of subjects: 326
Study 30670438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg twice weekly
Number of subjects: 326
Study 30670438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 450 mg daily
Number of subjects: 326
Study 30670438 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine 600 mg daily
Number of subjects: 326
Study 30670438 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 326
Study 30670438 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients carrying the AA variant of AADAC rs1803155
Number of subjects: 326
Study 27348211 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant + Risperidone
Number of subjects: 165
Study 27348211 — intervention group
Group type: COMPARATOR
Intervention: Stimulant + Placebo
Number of subjects: 165
Study 27348211 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulant only (baseline)
Number of subjects: 165
Study 26162826 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Sonothrombolysis (CEST)
Number of subjects: 0
Study 26162826 — intervention group
Group type: COMPARATOR
Intervention: Sham CEST
Number of subjects: 0
Study 26162826 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Alteplase with CEST
Number of subjects: 0
Study 26162826 — intervention group
Group type: COMPARATOR
Intervention: Routine Alteplase with Sham CEST
Number of subjects: 0
Study 26162826 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Sonolysis (CES)
Number of subjects: 0
Study 26162826 — intervention group
Group type: COMPARATOR
Intervention: Sham CES
Number of subjects: 0
Study 26162826 — intervention group
Group type: EXPERIMENTAL
Intervention: Favourable functional outcome defined as mRS 0-1 at 90 days
Number of subjects: 0
Study 26162826 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 24295876 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affect (NA)
Number of subjects: 82
Study 24295876 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid craving
Number of subjects: 82
Study 24295876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 82
Study 22880718 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography angiography (CTA)
Number of subjects: 257
Study 20817132 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (GTN)
Number of subjects: 77
Study 20817132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 17991656 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS/lcFOS supplementation (3 times/d with 3 g GOS/lcFOS at a ratio of 9:1)
Number of subjects: 48
Study 17991656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 48
Study 17991656 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS/lcFOS supplementation
Number of subjects: 48
Study 16302558 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.75% gel
Number of subjects: 33
Study 16302558 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid 15% gel
Number of subjects: 33
Study 16302558 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum (negative control)
Number of subjects: 33
Study 11948033 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 or 24 microg)
Number of subjects: 854
Study 11948033 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg)
Number of subjects: 854
Study 11948033 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 854
Study 11948033 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol and THEO
Number of subjects: 854
Study 11948033 — intervention group
Group type: COMPARATOR
Intervention: THEO
Number of subjects: 854
Study 11948033 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 854
Study 9794281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary tuberculosis patients (n=53)
Number of subjects: 53
Study 9794281 — intervention group
Group type: COMPARATOR
Intervention: Long-stay orthopedic patients with lower limb fractures (n=20)
Number of subjects: 53
Study 9794281 — intervention group
Group type: COMPARATOR
Intervention: Apparently healthy controls (n=20)
Number of subjects: 53
Study 8541696 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT-LCT (75% medium-chain triglyceride and 25% long-chain triglyceride)
Number of subjects: 10
Study 8541696 — intervention group
Group type: COMPARATOR
Intervention: LCT (100% long-chain triglyceride)
Number of subjects: 10
Study 8541696 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT-LCT
Number of subjects: 10
Study 2241001 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 290
Study 2241001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 113810 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo treatment for 1 week
Number of subjects: 241
Study 113810 — intervention group
Group type: COMPARATOR
Intervention: No medication (quasi-control)
Number of subjects: 241
Study 31004676 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide liquid formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Number of subjects: 308
Study 31004676 — intervention group
Group type: COMPARATOR
Intervention: Albiglutide lyophilized formulation (30 mg for 4 weeks, then 50 mg for 22 weeks)
Number of subjects: 308
Study 31004676 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide liquid formulation
Number of subjects: 308
Study 31004676 — intervention group
Group type: COMPARATOR
Intervention: Albiglutide lyophilized formulation
Number of subjects: 308
Study 26670990 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic exercise (10 rapid jump squats at 20% 1RM)
Number of subjects: 14
Study 26670990 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy exercise (5 heavy back squats at 80% 1RM)
Number of subjects: 14
Study 25029908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy for 2 years after immunochemotherapy
Number of subjects: 0
Study 25029908 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 25029908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0
Study 23438262 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mL/kg 0.9% saline bolus
Number of subjects: 224
Study 23438262 — intervention group
Group type: COMPARATOR
Intervention: 20 mL/kg 0.9% saline bolus
Number of subjects: 224
Study 21425571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligustrazine (2 mg/kg, intravenous dripping 30 min before auto-blood collection)
Number of subjects: 40
Study 21425571 — intervention group
Group type: COMPARATOR
Intervention: Control (no ligustrazine)
Number of subjects: 40
Study 19436018 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (alone or with dipyridamole)
Number of subjects: 5269
Study 19436018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin)
Number of subjects: 5269
Study 19436018 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (alone)
Number of subjects: 5269
Study 18005935 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 67
Study 18005935 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure with Imagery Rescripting (IE+IR)
Number of subjects: 67
Study 16972701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive design methodology
Number of subjects: 0
Study 12904684 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 162
Study 12904684 — intervention group
Group type: COMPARATOR
Intervention: Captopril (ACE inhibitor)
Number of subjects: 162
Study 12904684 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (calcium channel blocker)
Number of subjects: 162
Study 11033188 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen (O(2))
Number of subjects: 25
Study 11033188 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% carbogen (95% O(2), 5% CO(2))
Number of subjects: 25
Study 11033188 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% carbogen (97.5% O(2), 2.5% CO(2))
Number of subjects: 25
Study 8872690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg (Group LID)
Number of subjects: 90
Study 8872690 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg/kg (Group E1)
Number of subjects: 90
Study 8872690 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol 2 mg/kg (Group E2)
Number of subjects: 90
Study 8872690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg and Esmolol 1 mg/kg (Group LID-E1)
Number of subjects: 90
Study 8872690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg and Esmolol 2 mg/kg (Group LID-E2)
Number of subjects: 90
Study 8872690 — intervention group
Group type: COMPARATOR
Intervention: Saline as a placebo (Group PLAC)
Number of subjects: 90
Study 1504110 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg yohimbine orally
Number of subjects: 27
Study 1504110 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 27
Study 1504110 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam treatment
Number of subjects: 27
Study 1504110 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 27
Study 6096626 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.26 mg/kg)
Number of subjects: 29
Study 6096626 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 29
Study 30942030 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Zusanli (ST 36), once a day for 12 days
Number of subjects: 60
Study 30942030 — intervention group
Group type: COMPARATOR
Intervention: Routine symptomatic scheme (Control group)
Number of subjects: 60
Study 29074099 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting pasireotide (60 mg intramuscularly every 28 days)
Number of subjects: 124
Study 29074099 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (10 mg orally once daily)
Number of subjects: 124
Study 29074099 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long-acting pasireotide and everolimus
Number of subjects: 124
Study 26136351 — intervention group
Group type: COMPARATOR
Intervention: 20mg methylphenidate
Number of subjects: 28
Study 26136351 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature responses after prior feedback
Number of subjects: 28
Study 23218662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided surgery
Number of subjects: 134
Study 23218662 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided surgery
Number of subjects: 134
Study 21695666 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate endurance training (n=7)
Number of subjects: 21
Study 21695666 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (n=7)
Number of subjects: 21
Study 21695666 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 21
Study 18496950 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive technique for EC-IC bypass
Number of subjects: 39
Study 16643262 — intervention group
Group type: EXPERIMENTAL
Intervention: BASO II trial (treatment trial)
Number of subjects: 0
Study 16643262 — intervention group
Group type: EXPERIMENTAL
Intervention: IBIS (prevention trial)
Number of subjects: 0
Study 15260877 — intervention group
Group type: EXPERIMENTAL
Intervention: General movement experience
Number of subjects: 30
Study 15260877 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related movement experience
Number of subjects: 30
Study 15260877 — intervention group
Group type: COMPARATOR
Intervention: No movement experience
Number of subjects: 30
Study 11418256 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid and unpaid television and print‐media advertising, physician mail‐outs, and community‐level support programs and strategies
Number of subjects: 0
Study 11418256 — intervention group
Group type: COMPARATOR
Intervention: Comparison region (other states of Australia)
Number of subjects: 0
Study 9269694 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg daily
Number of subjects: 93
Study 9269694 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 93
Study 8277144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 671
Study 8277144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study 3828958 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 198
Study 3828958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 27820972 — intervention group
Group type: EXPERIMENTAL
Intervention: CL-GVS (cathode on the left mastoid)
Number of subjects: 24
Study 27820972 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-GVS (cathode on the right mastoid)
Number of subjects: 24
Study 27820972 — intervention group
Group type: COMPARATOR
Intervention: Sham-GVS
Number of subjects: 24
Study 26685849 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for 3 days
Number of subjects: 60
Study 26685849 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/metronidazole for 7 days
Number of subjects: 60
Study 24158845 — intervention group
Group type: EXPERIMENTAL
Intervention: First-eye phacoemulsification surgery
Number of subjects: 80
Study 24158845 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-eye phacoemulsification surgery
Number of subjects: 80
Study 24158845 — intervention group
Group type: COMPARATOR
Intervention: UV-blocking or blue-blocking IOL
Number of subjects: 80
Study 23747646 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training (6 times per week, twice daily for 10-20 minutes, for 6 weeks)
Number of subjects: 12
Study 23747646 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based treadmill training
Number of subjects: 12
Study 20032102 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2‐TNFR:Fc (1 x 10(11), 1 x 10(12), or 1 x 10(13) DNase‐resistant particles/ml joint volume)
Number of subjects: 127
Study 20032102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 19044302 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon
Number of subjects: 3
Study 19044302 — intervention group
Group type: COMPARATOR
Intervention: tamsulosin
Number of subjects: 3
Study 16683146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated preoperative radiotherapy (5x5 Gy)
Number of subjects: 148
Study 16683146 — intervention group
Group type: COMPARATOR
Intervention: TME/PME surgery alone
Number of subjects: 148
Study 14529892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 60
Study 14529892 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 60
Study 10759886 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with continuous intravenous infusion of antithrombin III and two intraperitoneal instillations of fresh frozen human donor serum
Number of subjects: 50
Study 10759886 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 50
Study 10759886 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with antithrombin III and serum
Number of subjects: 50
Study 8989857 — intervention group
Group type: EXPERIMENTAL
Intervention: Using a picture as an organizing cue for the second passage just before retrieval of the first passage
Number of subjects: 0
Study 8989857 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 1639655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy followed by local treatment and maintenance therapy
Number of subjects: 107
Study 1639655 — intervention group
Group type: COMPARATOR
Intervention: Radiation only to the intact breast and regional nodes
Number of subjects: 107
Study 1639655 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy followed by postoperative radiotherapy
Number of subjects: 107
Study 1639655 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 107
Study 6712858 — intervention group
Group type: EXPERIMENTAL
Intervention: prizidilol (n = 10)
Number of subjects: 22
Study 6712858 — intervention group
Group type: COMPARATOR
Intervention: propranolol (n = 12)
Number of subjects: 22
Study 31369607 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 12
Study 31369607 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 12
Study 30170898 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES)
Number of subjects: 69
Study 30170898 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 69
Study 26862008 — intervention group
Group type: EXPERIMENTAL
Intervention: Six meals per day
Number of subjects: 40
Study 26862008 — intervention group
Group type: COMPARATOR
Intervention: Three meals per day
Number of subjects: 40
Study 24246820 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month, gender-tailored SHED-IT Weight Loss Maintenance Program (n = 47)
Number of subjects: 92
Study 24246820 — intervention group
Group type: COMPARATOR
Intervention: Self-help control group (n = 45)
Number of subjects: 92